Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP -33.33% Earnings per Share (Diluted) is $-0.04 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,165 Biotechnology companies, Regen BioPharma ranks better than 64.21% on this metric.
Regen BioPharma's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.04.
During the past 3 years, the average EPS without NRIGrowth Rate was 28.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 32.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 53.00% per year.
During the past 13 years, Regen BioPharma's highest 3-Year average EPS without NRI Growth Rate was 79.20% per year. The lowest was -16.60% per year. And the median was 23.05% per year.
Regen BioPharma (OTCPK:RGBP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Regen BioPharma Earnings per Share (Diluted) Related Terms
Regen BioPharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma Earnings per Share (Diluted) Chart
RGBP vs IOBTQ, SCPX, LIPO: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Regen BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's PE Ratio falls into.
Regen BioPharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Regen BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.04 mean?
Regen BioPharma (RGBP) has a Earnings per Share (Diluted) of $-0.04 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #417 out of 1165 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Regen BioPharma's Earnings per Share (Diluted) too high?
Regen BioPharma's current Earnings per Share (Diluted) is $-0.04. Based on the distribution chart, Regen BioPharma ranks #417 out of 1165 companies in the Biotechnology industry, which is above the industry midpoint.
How does Regen BioPharma's Earnings per Share (Diluted) compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #417 out of 1165 companies for Earnings per Share (Diluted). This puts Regen BioPharma in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,165 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Earnings per Share (Diluted) is $-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Earnings per Share (Diluted) is $-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Earnings per Share (Diluted) is $-0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
